Fatigue, Pain, Soreness, Weakness
Conditions
Keywords
CoQ-10, statin, muscle pain, cardiovascular
Brief summary
This study will investigate whether a supplement called co-enzyme Q10 can help ease or eliminate some of the side effects that result from taking statin medications. These side effects include muscle pain, fatigue or muscle cramping.
Detailed description
Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and muscle function. This objective will be achieved in a randomized, placebo-controlled double blind trial by assessing the degree of muscle symptoms and interference of pain with daily activities, aerobic capacity, and muscle function before and after supplementation with either coQ10 or placebo in groups of statin-treated subjects. Specific Aim 2: to examine changes at a molecular/cellular level that are associated with improved pain and muscle function in statin-treated subjects supplemented with coQ10. This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients before and after supplementation with coQ10 or placebo.
Interventions
DIETARY_SUPPLEMENTCo-enzyme Q-10
Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
DIETARY_SUPPLEMENTPlacebo
Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
Sponsors
Stony Brook University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult men and women 21 years and older taking statin medications for hyperlipidemia under the current National Cholesterol Education Program guidelines (NCEP III) and complaining of myopathic symptoms.
Exclusion criteria
1. diagnosis of cancer; 2. acute illness of any sort; 3. hemoglobin less than 12, 4. creatinine greater than 1.5 mg/dl; 5. liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper limit of normal; 6. use of certain medications or nutritional supplements within the past month; 7. untreated hypertension (diastolic BP\> 100 mm HG); 8. diagnosis of diabetes mellitus (fasting blood glucose \> 126 mg/dl); 9. untreated hypothyroidism; 10. overt congestive heart failure (by physical exam); 11. active inflammatory diseases such as rheumatoid arthritis, lupus, etc., 12. bleeding disorders; 13. history of adverse reactions besides myopathy associated with the use of statins; 14. any previous adverse reaction to coQ10 or to multivitamin supplements containing coQ10; 15. plasma CPK levels \> 3 times the upper normal limit; OR 16. congenital myopathies and/or neuromuscular degenerative diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain scores should be reduced | 8 weeks |
Countries
United States
Outcome results
None listed